Evidence map›Paper›PMID 39172350›Full record

ArticleInfection2025

Patients with immune mediated inflammatory diseases are insufficiently protected against vaccine-preventable infections.

Natasja van de Pol, C Janneke van der Woude, Marijn Vis, Martijn B A van Doorn, Saskia L Schrauwen, Fatos Cetinözman-Teunissen, Rachel L West, Annemarie C de Vries

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Natasja van de PolDepartment of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
C Janneke van der WoudeDepartment of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Marijn VisDepartment of Rheumatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Martijn B A van DoornDepartment of Dermatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Saskia L SchrauwenDepartment of Rheumatology, Franciscus Gasthuis and Vlietland Hospital, Rotterdam, the Netherlands.
Fatos Cetinözman-TeunissenDepartment of Dermatology, Franciscus Gasthuis and Vlietland Hospital, Rotterdam, the Netherlands.
Rachel L WestDepartment of Gastroenterology and Hepatology, Franciscus Gasthuis and Vlietland Hospital, Rotterdam, the Netherlands.
Annemarie C de VriesDepartment of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands. a.c.devries@erasmusmc.nl.

Funding

Pfizer Pharmaceuticals 68985113
6 · The paper itself

Abstract

backgroundPatients with Immune Mediated Inflammatory Diseases (IMIDs) using immunosuppressive therapy are at increased risk of infections, including vaccine-preventable infections. In this study, we aimed to evaluate whether patients with IMIDs on systemic immunosuppressive therapy are vaccinated according to current guidelines.

methodsA survey was sent out, between August 2022 and March 2023, to all patients with IMIDs that visited the departments of dermatology, rheumatology and gastroenterology at an academic and regional hospital in Rotterdam, the Netherlands. Patient-reported vaccination status was compared to the Dutch guidelines on vaccinations in patients with chronic inflammatory diseases.

resultsA total of 1,905/5,987 patients responded to the survey (response rate 32%). After exclusion of patients without systemic immunosuppressive medication, the study population comprised 1,390 patients, median age 56 years (IQR 42-66) and 41% male. Most patients (92%) had been vaccinated according to the Dutch National Immunization Program. Before starting immunosuppressive therapy, 2% of the patients who were still considered at risk according to the Dutch guideline were vaccinated for measles, and 4% for diphtheria/tetanus/polio (DT-IPV). Additionally, 62% of patients received an annual influenza vaccine, 16% received a five-yearly pneumococcal vaccine, and 91% were fully vaccinated against COVID-19.

conclusionPatients with IMIDs on immunosuppressive therapy are not vaccinated in accordance with the guidelines. Implementation strategies to improve the vaccination rates for patients with IMIDs should specifically focus on vaccinating against measles and diphtheria/tetanus/polio, and periodic vaccination against pneumococcal and influenza infections.

Indexed as

Immunosuppressive AgentsVaccinationVaccine-Preventable DiseasesAdultAgedFemaleHumansImmunocompromised HostInfluenza VaccinesMaleMiddle AgedNetherlandsSurveys and QuestionnairesImmunosuppressive AgentsInfluenza VaccinesImmune mediated inflammatory diseasesImmunocompromised patientsVaccination careVaccine coverage

Identifiers

PMID39172350
PMCPMC11825543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.